Thromb Haemost 1975; 34(02): 483-497
DOI: 10.1055/s-0038-1651407
Original Article
Schattauer GmbH

Blood Changes in Atherosclerosis and Long After Myocardial Infarction and Venous Thrombosis

John R O’Brien
1   Portsmouth & S. E. Hampshire Health District Pathology Service, Portsmouth, Portsmouth Polytechnic, and Dept. of Enzymology, Washington University, St. Louis, Missouri, U.S.A.
,
Michael D Etherington
1   Portsmouth & S. E. Hampshire Health District Pathology Service, Portsmouth, Portsmouth Polytechnic, and Dept. of Enzymology, Washington University, St. Louis, Missouri, U.S.A.
,
Sandra Jamieson
1   Portsmouth & S. E. Hampshire Health District Pathology Service, Portsmouth, Portsmouth Polytechnic, and Dept. of Enzymology, Washington University, St. Louis, Missouri, U.S.A.
,
Piers Lawford
1   Portsmouth & S. E. Hampshire Health District Pathology Service, Portsmouth, Portsmouth Polytechnic, and Dept. of Enzymology, Washington University, St. Louis, Missouri, U.S.A.
,
S. V Lincoln
1   Portsmouth & S. E. Hampshire Health District Pathology Service, Portsmouth, Portsmouth Polytechnic, and Dept. of Enzymology, Washington University, St. Louis, Missouri, U.S.A.
,
Norma J Alkjaersig
1   Portsmouth & S. E. Hampshire Health District Pathology Service, Portsmouth, Portsmouth Polytechnic, and Dept. of Enzymology, Washington University, St. Louis, Missouri, U.S.A.
› Author Affiliations
Further Information

Publication History

Received 08 January 1975

accepted 16 May 1975

Publication Date:
02 July 2018 (online)

Summary

The following clinical groups of volunteers were studied: patients long after recovery from myocardial infarction (MI), others after recovery from deep vein thrombosis (DVT), patients with intermittent claudication, with diabetes, and male and female controls who were well matched. All were subjected to many platelet and clotting tests together with clinical, biochemical and haematological measurements in an attempt to find long term abnormalities in these various diseases.

The male Mis differed very significantly from the controls in having much more heparin neutralizing activity (P < 0.001) and less anti-thrombin (P < 0.01). Less significantly, some bleeding time tests indicated less bleeding and the patients’ platelets were larger. The females with MI had in general the same abnormalities but to a lesser degree. The patients with intermittent claudication, none of whom had a history of MI, had almost the same abnormalities and to the same degree. In deep vein thrombosis the heparin neutralizing activity was also clearly increased; the other tests were generally in the same direction but many were not significant. The diabetics had shorter bleeding times but little else abnormal relative to the controls, suggesting a different pathological process.

When all male patients and controls were “scored” according to the degree of atherosclerosis there was a close overall correlation between the degree of atherosclerosis and the increase in the HNA level (r = — 0.50, n = 66, P < 0.001) and the decreased anti-thrombin (r = — 0.25, n = 66, P < 0.05).

The platelet abnormalities might indicate activated platelets with increased turnover; decreased anti-thrombin not only favours clotting but could suggest that clotting has occurred. Thus it is suggested that all the abnormalities may be accounted for if minor intravascular or mural coagulation occurs more or less permanently in these patients. This activation of the haemostatic mechanism towards coagulation could be related to the cause of atherosclerosis, or it could be the result. The mechanisms predisposing to or following DVT are somewhat different ; some may be shared. The nine diabetics are clearly quite different.

The reported abnormalities found consistently in two studies may (1) illuminate pathogenesis; (2) indicate groups or even individuals at risk. (3) Improvement of the tests by appropriate therapy might justify a clinical trial of that therapy. (4) The high HNA in these syndromes may be relevant to any contemplated heparin therapy.

 
  • References

  • 1 Alkjaersig N, Boy L, Fletcher A, and Murphy E. 1973; Analysis of gel exclusion chromatographic data by chromatographic plate theory analysis: Application to plasma fibrinogen chromatography. Thrombosis Research 3: 525.
  • 2 Biggs R, Denson K. E, Akman N, Borrett R, and Hadden M. 1970; Antithrombin III, anti-Factor Xa and heparin. British Journal of Haematology 19: 283.
  • 3 Duguid J. B. 1946; Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. Journal of Pathology and Bacteriology 58: 207.
  • 4 Egeberg O. 1965; Inherited anti-thrombin deficiency causing thrombophilia. Thrombosis et Diathesis Haemorrhagica 13: 516.
  • 5 Fletcher A. P, Alkjaersig N, Roy L, and Owens O. 1973; Early detection of blood hypercoagulable states and early thromboembolic lesions in man. Technicon International Congress 4: 31.
  • 6 Karpatkin S. 1972; Human platelet senescence. Annual Review of Medicine 23: 953.
  • 7 Mancini G, Carbonara A, and Heremans J. F. 1965; Immunochemical quantifications of antigens by single radial immunodiffusion. International Journal of Immunochemistry 2: 235.
  • 8 Mielke C. H, Kaneshiro M. M, Maher I. A, Wessler J. M, and Rapaport S. I. 1969; The standardised Ivy bleeding time and its prolongation by aspirin. Blood 34: 204.
  • 9 Murphy E. A, and Mustard J. F. 1962; Coagulation tests and platelet economy in atherosclerotic and control subjects. Circulation 25: 114.
  • 10 O’Brien J. R. 1951; The bleeding time in normal and abnormal subjects. Journal of Clinical Pathology 4: 272.
  • 11 O’Brien J. R. 1974; Anti-thrombin III and heparin clotting times in thrombosis and atherosclerosis. Thrombosis et Diathesis Haemorrhagica 32: 116.
  • 12 O’Brien J. R, Etherington M. D, and Jamieson S. 1971; Refractory state of platelet aggregation with major operations. Lancet 2: 741.
  • 13 O’Brien J. R, Etherington M. D, Jamieson S, and Klaber M. R. 1973; Stressed template bleeding time and other platelet function tests in myocardial infarction. Lancet 1: 694.
  • 14 O’Brien J. R, Etherington M. D, Jamieson S, Klaber M. R, and Lincoln S. V. 1974; a Platelet function long after arterial and venous thrombosis. Thrombosis et Diathesis Haemorrhagica 31: 279.
  • 15 O’Brien J. R, Etherington M. D, Jamieson S, and Lawford P. 1974; b Heparin thrombin clotting time and platelet factor 4. Lancet 2: 656.
  • 16 Praga C, Cortellaro M, and Pogliani E. 1972. Standardised bleeding time in the study of drugs interfering with platelet function. In: Mannucci P. M, and Gorini S. (eds.) Platelet Function in Thrombosis: A Bevieiv of Methods. Plenum Press; New York: 149.
  • 17 von Kaulla E, and von Kaulla K. N. 1967; Anti-thrombin III and disease. American Journal of Clinical Pathology 48: 69.
  • 18 Yin E. T, Wessler S, and Stoll P. J. 1971; Identity of plasma-activated Factor X inhibitor with anti-thrombin III and heparin cofactor. Journal of Biological Chemistry 246: 3712.